This is a StreetInsider.com Premium Only Page

RespireRx Pharmaceuticals Inc. (RSPI) –

Apr 16, 2024 04:06 PM Form 8-K RespireRx Pharmaceutical For: Apr 10

Apr 1, 2024 04:06 PM Form NT 10-K RespireRx Pharmaceutical For: Dec 31

Feb 2, 2024 08:31 AM Form 8-K RespireRx Pharmaceutical For: Jan 30

Jan 22, 2024 08:46 AM Form 8-K RespireRx Pharmaceutical For: Jan 18

Dec 11, 2023 08:46 AM Form 8-K RespireRx Pharmaceutical For: Dec 06

Nov 17, 2023 04:07 PM Form 10-Q RespireRx Pharmaceutical For: Sep 30

Nov 14, 2023 04:40 PM Form NT 10-Q RespireRx Pharmaceutical For: Sep 30

Oct 12, 2023 09:00 AM Form 8-K RespireRx Pharmaceutical For: Oct 09

Oct 2, 2023 08:46 AM Form 8-K RespireRx Pharmaceutical For: Sep 26

Aug 21, 2023 04:06 PM Form 10-Q RespireRx Pharmaceutical For: Jun 30

Aug 14, 2023 04:27 PM Form NT 10-Q RespireRx Pharmaceutical For: Jun 30

Aug 9, 2023 08:52 AM Form 8-K RespireRx Pharmaceutical For: Aug 03

Jun 13, 2023 04:11 PM Form 8-K RespireRx Pharmaceutical For: Jun 07

May 24, 2023 08:45 AM Form 8-K RespireRx Pharmaceutical For: May 18

May 24, 2023 08:30 AM ResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development Costs

May 22, 2023 04:16 PM Form 10-Q RespireRx Pharmaceutical For: Mar 31

May 15, 2023 04:08 PM Form NT 10-Q RespireRx Pharmaceutical For: Mar 31

May 5, 2023 04:06 PM Form 8-K RespireRx Pharmaceutical For: May 01

Apr 17, 2023 04:19 PM Form 10-K RespireRx Pharmaceutical For: Dec 31

Apr 13, 2023 08:30 AM Form 8-K RespireRx Pharmaceutical For: Apr 12

Apr 6, 2023 08:31 AM Form 8-K RespireRx Pharmaceutical For: Apr 03

Apr 5, 2023 08:30 AM RespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders

Apr 3, 2023 08:30 AM RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation.

Mar 31, 2023 04:20 PM Form NT 10-K RespireRx Pharmaceutical For: Dec 31

Mar 28, 2023 08:56 AM Form 8-K RespireRx Pharmaceutical For: Mar 22

Mar 28, 2023 08:32 AM RespireRx Pharmaceuticals (RSPI) Appoints Joseph Siegelbaum to its Board

Mar 28, 2023 08:30 AM RespireRx Pharmaceuticals Inc. Announces the Appointment Joseph Siegelbaum as an Independent Member of the Board of Directors

Mar 1, 2023 08:52 AM Form 8-K RespireRx Pharmaceutical For: Feb 27

Mar 1, 2023 08:30 AM ResolutionRx Ltd and RespireRx Pharmaceuticals Inc. Announce ResolutionRx’s Entry into a Services Agreement with iNGENu CRO Pty Ltd

Feb 1, 2023 08:46 AM Form 8-K RespireRx Pharmaceutical For: Jan 27

Feb 1, 2023 08:30 AM ResolutionRx Ltd, a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. Enters into LOI and Term Sheet with Radium Capital for the financing of anticipated Research and Development Credits

Jan 23, 2023 08:46 AM Form 8-K RespireRx Pharmaceutical For: Jan 18

Jan 23, 2023 08:30 AM RespireRx Pharmaceuticals Inc. Announces the 2nd Amendment to its License Agreement with the University of Illinois

Jan 12, 2023 09:01 AM Form 8-K RespireRx Pharmaceutical For: Jan 11

Jan 12, 2023 08:30 AM RespireRx Pharmaceuticals Inc. Establishes ResolutionRx Ltd in Australia to Develop Its Pharmaceutical Cannabinoid Platform

Dec 5, 2022 08:30 AM RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development

Nov 17, 2022 04:08 PM Form 10-Q RespireRx Pharmaceutical For: Sep 30

Nov 17, 2022 09:00 AM Form 8-K RespireRx Pharmaceutical For: Nov 14

Nov 17, 2022 08:45 AM RespireRx Pharmaceuticals Inc. Announces Entry into Letter of Intent with Australian Headquartered CRO for Dronabinol Development for Obstructive Sleep Apnea

Nov 14, 2022 04:36 PM Form NT 10-Q RespireRx Pharmaceutical For: Sep 30

Nov 10, 2022 09:02 AM Form 8-K RespireRx Pharmaceutical For: Nov 10

Nov 10, 2022 08:45 AM RespireRx Pharmaceuticals Inc. Announces that Jeff Margolis, the Company’s CFO is presenting at the Investor Summit Q4

Nov 7, 2022 09:01 AM Form 8-K RespireRx Pharmaceutical For: Nov 07

Nov 7, 2022 08:45 AM RespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa Is an Invited Speaker at the 5th Meridian Drug Discovery Summit

Sep 13, 2022 04:06 PM Form 8-K RespireRx Pharmaceutical For: Sep 07

Aug 22, 2022 04:06 PM Form 10-Q RespireRx Pharmaceutical For: Jun 30

Aug 15, 2022 04:14 PM Form NT 10-Q RespireRx Pharmaceutical For: Jun 30

Aug 8, 2022 08:00 AM RespireRx Pharmaceuticals Inc. Announces that Sleep Review has discussed the RespireRx Dronabinol Obstructive Sleep Apnea (OSA) Program in its June 13, 2022 Edition

Aug 3, 2022 04:06 PM Form 8-K RespireRx Pharmaceutical For: Jul 31

Jun 16, 2022 08:33 AM Form 8-K RespireRx Pharmaceutical For: Jun 15